Clinical evidence for multiple dopamine receptors in man

Herbert Y. Meltzer*

*Corresponding author for this work

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The dopaminergic receptors in man appear to have much the same diversity and similarity as those present in laboratory animals. Most but not all, dopamine (DA) receptor blocking drugs have comparable effects on a variety of behaviors or chemical indices of anti-dopaminergic activity at postsynaptic DA receptors [antipsychotic action, extrapyramidal side effects, anti-emesis, increased cerebrospinal fluid (CSF) homovanillac acid (HVA), or serum prolactin stimulation] suggesting similar DA receptors in the striatal, limbic and cortical brain regions and the pituitary. Several drugs are exceptions, e.g., clozapine and sulpiride, raising the possibility these drugs affect other DA receptors or act via non-dopaminergic mechanisms. The presence of autoreceptors on striatal, limbic or cortical DA neurons is supported by a variety of clinical studies involving apomorphine, piribedil or bromocriptine administration to normal controls, psychotic patients and patients with Parkinson's disease, tardive dyskinesia or Huntington's chorea. [3H]-Spiroperidol binding studies also suggest different DA receptors in the human cortex and caudate. A DA-sensitive adenylate cyclase has been found in the human brain. Glial DA receptors have been proposed.

Original languageEnglish (US)
Pages (from-to)457-470
Number of pages14
JournalCommunications In Psychopharmacology
Volume3
Issue number6
StatePublished - Dec 1 1979

Fingerprint

Dopamine Receptors
Corpus Striatum
Piribedil
Pharmaceutical Preparations
Spiperone
Autoreceptors
Sulpiride
Bromocriptine
Apomorphine
Clozapine
Dopaminergic Neurons
Huntington Disease
Brain
Laboratory Animals
Adenylyl Cyclases
Neuroglia
Prolactin
Antipsychotic Agents
Vomiting
Parkinson Disease

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{b1d87520574e436db85b9010374e971f,
title = "Clinical evidence for multiple dopamine receptors in man",
abstract = "The dopaminergic receptors in man appear to have much the same diversity and similarity as those present in laboratory animals. Most but not all, dopamine (DA) receptor blocking drugs have comparable effects on a variety of behaviors or chemical indices of anti-dopaminergic activity at postsynaptic DA receptors [antipsychotic action, extrapyramidal side effects, anti-emesis, increased cerebrospinal fluid (CSF) homovanillac acid (HVA), or serum prolactin stimulation] suggesting similar DA receptors in the striatal, limbic and cortical brain regions and the pituitary. Several drugs are exceptions, e.g., clozapine and sulpiride, raising the possibility these drugs affect other DA receptors or act via non-dopaminergic mechanisms. The presence of autoreceptors on striatal, limbic or cortical DA neurons is supported by a variety of clinical studies involving apomorphine, piribedil or bromocriptine administration to normal controls, psychotic patients and patients with Parkinson's disease, tardive dyskinesia or Huntington's chorea. [3H]-Spiroperidol binding studies also suggest different DA receptors in the human cortex and caudate. A DA-sensitive adenylate cyclase has been found in the human brain. Glial DA receptors have been proposed.",
author = "Meltzer, {Herbert Y.}",
year = "1979",
month = "12",
day = "1",
language = "English (US)",
volume = "3",
pages = "457--470",
journal = "Communications in Psychopharmacology",
issn = "0145-5699",
number = "6",

}

Clinical evidence for multiple dopamine receptors in man. / Meltzer, Herbert Y.

In: Communications In Psychopharmacology, Vol. 3, No. 6, 01.12.1979, p. 457-470.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Clinical evidence for multiple dopamine receptors in man

AU - Meltzer, Herbert Y.

PY - 1979/12/1

Y1 - 1979/12/1

N2 - The dopaminergic receptors in man appear to have much the same diversity and similarity as those present in laboratory animals. Most but not all, dopamine (DA) receptor blocking drugs have comparable effects on a variety of behaviors or chemical indices of anti-dopaminergic activity at postsynaptic DA receptors [antipsychotic action, extrapyramidal side effects, anti-emesis, increased cerebrospinal fluid (CSF) homovanillac acid (HVA), or serum prolactin stimulation] suggesting similar DA receptors in the striatal, limbic and cortical brain regions and the pituitary. Several drugs are exceptions, e.g., clozapine and sulpiride, raising the possibility these drugs affect other DA receptors or act via non-dopaminergic mechanisms. The presence of autoreceptors on striatal, limbic or cortical DA neurons is supported by a variety of clinical studies involving apomorphine, piribedil or bromocriptine administration to normal controls, psychotic patients and patients with Parkinson's disease, tardive dyskinesia or Huntington's chorea. [3H]-Spiroperidol binding studies also suggest different DA receptors in the human cortex and caudate. A DA-sensitive adenylate cyclase has been found in the human brain. Glial DA receptors have been proposed.

AB - The dopaminergic receptors in man appear to have much the same diversity and similarity as those present in laboratory animals. Most but not all, dopamine (DA) receptor blocking drugs have comparable effects on a variety of behaviors or chemical indices of anti-dopaminergic activity at postsynaptic DA receptors [antipsychotic action, extrapyramidal side effects, anti-emesis, increased cerebrospinal fluid (CSF) homovanillac acid (HVA), or serum prolactin stimulation] suggesting similar DA receptors in the striatal, limbic and cortical brain regions and the pituitary. Several drugs are exceptions, e.g., clozapine and sulpiride, raising the possibility these drugs affect other DA receptors or act via non-dopaminergic mechanisms. The presence of autoreceptors on striatal, limbic or cortical DA neurons is supported by a variety of clinical studies involving apomorphine, piribedil or bromocriptine administration to normal controls, psychotic patients and patients with Parkinson's disease, tardive dyskinesia or Huntington's chorea. [3H]-Spiroperidol binding studies also suggest different DA receptors in the human cortex and caudate. A DA-sensitive adenylate cyclase has been found in the human brain. Glial DA receptors have been proposed.

UR - http://www.scopus.com/inward/record.url?scp=0018627024&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018627024&partnerID=8YFLogxK

M3 - Article

C2 - 44694

AN - SCOPUS:0018627024

VL - 3

SP - 457

EP - 470

JO - Communications in Psychopharmacology

JF - Communications in Psychopharmacology

SN - 0145-5699

IS - 6

ER -